Caplin Point Laboratories liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

27.38×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
6.70×	6.70×	6.97×	5.72×	5.80×
5.59×	5.59×	5.87×	4.63×	4.72×
480	480	511	377	337
2,200	2,200	1,828	1,562	1,286

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CAPLIPOINT₹2,213.40

Caplin Point Laboratories Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM ERIS GLAND BLUEJET CONCORDBIO ACUTAAS EMCURE GRANULESMcap ₹16,822 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	27.38
Current Ratio	5.80	5.72	6.97	6.70	6.70
Quick Ratio	4.72	4.63	5.87	5.59	5.59
Cash, Equiv & ST Investments	336.7	376.7	510.8	479.9	479.9
Working Capital	1,286.5	1,561.7	1,827.6	2,199.7	2,199.7

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.